Literature DB >> 6448893

Regulation of lymphocyte responses by human gangliosides. I. Characteristics of inhibitory effects and the induction of impaired activation.

R L Whisler, A J Yates.   

Abstract

Gangliosides obtained from normal human brain were found to inhibit the in vitro activation of human lymphocytes by nonspecific mitogens and allogeneic cells at concentrations between 3 to 50 microgram/1.5 to 1.7 X 10(5) lymphocytes/0.2 ml culture. Ganglioside inhibition did not represent cytotoxic effects or altered lectin binding and was independent of the mitogen concentration. In addition to concentration, the degree of inhibition was dependent on the mode of presentation to lymphocytes, since gangliosides incorporated within liposomal membranes displayed a synergistic inhibitory effect greater than predicted from the cultures receiving either gangliosides or liposomes alone. In binding experiments, radiolabeled ganglioside GM1 became associated with human lymphocytes within 10 min. However, approximately 72 hr pre-exposure of human lymphocytes to gangliosides was required to induce impaired lymphocyte responses to mitogens and allogeneic cells. Thus, concentrations of human gangliosides equivalent to the levels occurring in the sera of patients with certain malignancies are capable of actively inhibiting lymphocyte stimulation in addition to inducing impaired lymphocyte responses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6448893

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Effects of ganglioside (Cronassial) treatment on MHC Ia antigen expression and allograft survival of pancreatic islets in diabetic rats.

Authors:  R G Bretzel; B K Flesch; J Willig; M Woehrle; K Federlin
Journal:  Diabetologia       Date:  1990-02       Impact factor: 10.122

2.  Exogenously administered gangliosides fail to increase in vivo metastatic frequency or in vitro growth of murine neoplastic cells.

Authors:  L Facci; S D Skaper; D Presti; G Kirschner; A Leon; L Chieco-Bianchi
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

3.  Activation of human T lymphocytes by ganglioside-containing liposomes.

Authors:  K Yanagihara; E Kato; S Hitomi; J Sunamoto; H Wada
Journal:  Glycoconj J       Date:  1999-01       Impact factor: 2.916

Review 4.  Suppressor lipid-protein complexes of normal human serum.

Authors:  R L Wolf
Journal:  Surv Immunol Res       Date:  1982

5.  Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2.

Authors:  R Li; D Gage; R McKallip; S Ladisch
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

6.  Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.

Authors:  Jun-Eui Park; Dianna Y Wu; Maria Prendes; Sharon X Lu; Govind Ragupathi; Nicolas Schrantz; Paul B Chapman
Journal:  Immunology       Date:  2008-01       Impact factor: 7.397

7.  Ceramide structure predicts tumor ganglioside immunosuppressive activity.

Authors:  S Ladisch; R Li; E Olson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

8.  Gangliosides shed by tumor cells enhance tumor formation in mice.

Authors:  S Ladisch; S Kitada; E F Hays
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

9.  Behavior of sugar derivatives in procedures for ganglioside isolation.

Authors:  A J Yates; J K Warner
Journal:  Lipids       Date:  1984-07       Impact factor: 1.880

Review 10.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.